Talk about big online meetings! Up to 22,000 participants at once attended the free, virtual sessions at ESC Congress: The Digital Experience, Aug. 29 – Sept. 1st. A total of 115,000 people from around the world registered, and altogether 75,000 total users watched, according to event co-chair Marco Roffi.
If you missed PHRI scientists’ presentations at ESC 2020, you can watch them on-demand (after logging in)…
Watch PHRI Senior Scientist John Eikelboom as he presents twice, and participates as a panelist in the session, NOACs in patients with atrial fibrillations: insights from the cardiac cath lab.
Isabelle Johansson
Watch Isabelle Johansson, PHRI Research Fellow, present on G-CHF study: Health-related quality of life and clinical outcomes, part of the “Latest Findings in Heart Failure” session. (More on G-CHF.)
Watch PHRI Senior Scientist Shamir Mehta present COMPLETE: Bystander disease in STEMI, as part of the session, STEMI Trials: the Latest Results. (More on the landmark COMPLETE study.) He also presented on PCI in NSTEMI and multi-vessel disease.
Watch Sonia Anand, a PHRI Senior Scientist, present “My top 5 innovations – focus on anti-coagulation,” as part of: Celebration of the Last Decade of Cardiac Innovation: What has been achieved and what are the unmet needs.
Watch PHRI Scientist Andrew Mente take the “con” side in a debate about plant-based diet as the best for cardiovascular disease prevention as part of the “Risk Factors and Prevention” channel. Citing data from the PURE study, he focused on the benefits of diet variation and moderation.
Other PHRI research shared at ESC Congress 2020:
Richard Whitlock, a PHRI Scientist, in a rapid-fire abstracts session, Vitamin K antagonists versus direct oral anticoagulants after cardiac surgery: a 31-country cohort study (LAAOS III).
PHRI Investigator Flavia Borges on a biomarkers cohort study of 4,545 patients from the VISION study, in her e-poster session, High-sensitivity troponin I predicts major cardiovascular events after noncardiac surgery.
Related to PHRI’s landmark COMPASS study:
- Efficacy and safety of low-dose rivaroxaban on top of aspirin in patients with polypharmacy and multi-morbidity: an analysis from the COMPASS trial. Optimizing management of chronic CAD: Squeeze on Big Data for additional info.
- CHA2DS2-VASc and CHADS2 scores for the risk stratification of major adverse cardiovascular events in the COMPASS trial. Atrial fibrillation, platelet aggregation and outcomes.
